FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Heike Wulff

Research Profile

Chemicals & Drugs

Anatomy

Procedures

Patch-Clamp Techniques

Living Beings

Genes & Molecular Sequences

Amino Acid Sequences

Concepts & Ideas

Molecular Sequence Data

Physiology

Co-author Network

Publications

TOP 3
Pierre-Olivier Girodet; Olga Ilina; Roger Marthan; Olga Ousova; Annaig Ozier; Heike Wulff; Hugues Begueret; Peter Bradding; Gabrielle Carvalho; Alain-Pierre Gadeau; Patrick Berger
Ca(2+)-activated K(+) channel-3.1 blocker TRAM-34 attenuates airway remodeling and eosinophilia in a murine asthma model.
Ramesh C Mishra; Heike Wulff; Darrell Belke; Andrew P Braun
SKA-31, a novel activator of SK(Ca) and IK(Ca) channels, increases coronary flow in male and female rat hearts.
Heike Wulff; Ralf Köhler
Endothelial small-conductance and intermediate-conductance KCa channels: an update on their pharmacology and usefulness as cardiovascular targets.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Heike Wulff (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Pierre-Olivier Girodet; Olga Ilina; Roger Marthan; Olga Ousova; Annaig Ozier; Heike Wulff; Hugues Begueret; Peter Bradding; Gabrielle Carvalho; Alain-Pierre Gadeau; Patrick Berger
Ca(2+)-activated K(+) channel-3.1 blocker TRAM-34 attenuates airway remodeling and eosinophilia in a murine asthma model.
American journal of respiratory cell and molecular biology 2013;48(2):212-9.
2013: Ramesh C Mishra; Heike Wulff; Darrell Belke; Andrew P Braun
SKA-31, a novel activator of SK(Ca) and IK(Ca) channels, increases coronary flow in male and female rat hearts.
Cardiovascular research 2013;97(2):339-48.
2013: Heike Wulff; Ralf Köhler
Endothelial small-conductance and intermediate-conductance KCa channels: an update on their pharmacology and usefulness as cardiovascular targets.
Journal of cardiovascular pharmacology 2013;61(2):102-12.
2013: Aida Oliván-Viguera; Marta Sofía Valero; Heike Wulff; José-Miguel Arbonés-Mainar; Angel Luis García-Otín; María Divina Murillo; Ralf Köhler
Novel phenolic inhibitors of small/intermediate-conductance Ca²⁺-activated K⁺ channels, KCa3.1 and KCa2.3.
PloS one 2013;8(3):e58614.
2013: Dorte Strøbaek; Heike Wulff; D T Brown; D P Jenkins; Y Ando; Y-J Chen; P Chiu; N Coleman; J Demnitz; S Jørgensen; palle christophersen
NS6180, a new K(Ca) 3.1 channel inhibitor prevents T-cell activation and inflammation in a rat model of inflammatory bowel disease.
British journal of pharmacology 2013;168(2):432-44.
2012: Benjamin E Jin; Jonathan H Widdicombe; Heike Wulff; Jie Zheng; Donald M Bers; Jose L Puglisi
A simple device to illustrate the Einthoven triangle.
Advances in physiology education 2012;36(4):319-24.
2012: William Nguyen; Philip E Thompson; Heike Wulff; Brittany L Howard; David P Jenkins; David T Manallack
Structure-activity relationship exploration of Kv1.3 blockers based on diphenoxylate.
Bioorganic & medicinal chemistry letters 2012;22(23):7106-9.
2012: Thomas Vandendriessche; Elke Vermassen; Heike Wulff; Yousra Abdel-Mottaleb; Elke Clynen; Elia Diego-Garcia; David Paul Jenkins; Ivan Kopljar; Liliane Schoofs; Dirk J Snyders; Jan Tytgat
Purification, molecular cloning and functional characterization of HelaTx1 (Heterometrus laoticus): the first member of a new κ-KTX subfamily.
Biochemical pharmacology 2012;83(9):1307-17.
2012: Victor Chi; Shawn Iadonato; Jonathan T Lakey; Luz M Londono; Raymond S Norton; Michael Pennington; Brian Sims-Fahey; Eric J Tarcha; Sanjeev K Upadhyay; Heike Wulff; Christine Beeton; K George Chandy
Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases.
Toxicon : official journal of the International Society on Toxinology 2012;59(4):529-46.
2012: Kate Lykke Lambertsen; Aida Oliván-Viguera; Maj Rabjerg; Linda Maria Sevelsted-Møller; Mithula Sivasaravanaparan; Heike Wulff; Nicholas Ditzel; Jan Bert Gramsbergen; Ralf Köhler
Genetic KCa3.1-deficiency produces locomotor hyperactivity and alterations in cerebral monoamine levels.
PloS one 2012;7(10):e47744.
2012: Silke B Bodendiek; Nichole Coleman; David Paul Jenkins; Clio Rubinos; Maria Pilar Trelles; Heike Wulff; Miduturu Srinivas
Triarylmethanes, a new class of cx50 inhibitors.
Frontiers in pharmacology 2012;3():106.
2012: Izumi Maezawa; David Paul Jenkins; Benjamin E Jin; Heike Wulff
Microglial KCa3.1 Channels as a Potential Therapeutic Target for Alzheimer's Disease.
International journal of Alzheimer's disease 2012;2012():868972.
2012: Mads Damkjaer; Cor de Wit; Jan Bert Gramsbergen; Boye L Jensen; Gorm Nielsen; Simonsen Ulf; Mette Staehr; Heike Wulff; Peter Bie; Silke Bodendiek; Ralf Köhler
Pharmacological activation of KCa3.1/KCa2.3 channels produces endothelial hyperpolarization and lowers blood pressure in conscious dogs.
British journal of pharmacology 2012;165(1):223-34.
2011: Yi-Je Chen; Martha E O'Donnell; Girija Raman; Silke Bodendiek; Heike Wulff
The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2011;31(12):2363-74.
2011: Vikram Shakkottai; Heike Wulff; James M Dell'Orco; Maria do Carmo Costa; Ananthakrishnan Sankaranarayanan; Henry L Paulson
Early changes in cerebellar physiology accompany motor dysfunction in the polyglutamine disease spinocerebellar ataxia type 3.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2011;31(36):13002-14.
2011: A-L Hasenau; Christophe Morisseau; G Nielsen; Heike Wulff; Bruce D Hammock; R Köhler
Improvement of endothelium-dependent vasodilations by SKA-31 and SKA-20, activators of small- and intermediate-conductance Ca2+ -activated K+ -channels.
Acta physiologica (Oxford, England) 2011;203(1):117-26.
2011: David Paul Jenkins; Dorte Strøbaek; Charlotte Hougaard; Marianne L Jensen; Rene Hummel; Ulrik S Sørensen; Palle Christophersen; Heike Wulff
Negative gating modulation by (R)-N-(benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphthylamine (NS8593) depends on residues in the inner pore vestibule: pharmacological evidence of deep-pore gating of K(Ca)2 channels.
Molecular pharmacology 2011;79(6):899-909.
2011: B Hao; Z-W Chen; X-J Zhou; P I Zimin; G P Miljanich; Heike Wulff; Y-X Wang
Identification of phase-I metabolites and chronic toxicity study of the Kv1.3 blocker PAP-1 (5-(4-phenoxybutoxy)psoralen) in the rat.
Xenobiotica; the fate of foreign compounds in biological systems 2011;41(3):198-211.
2011: Izumi Maezawa; Pavel I Zimin; Heike Wulff; Lee-Way Jin
Amyloid-beta protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity.
The Journal of biological chemistry 2011;286(5):3693-706.
2011: Izumi Maezawa; Heike Wulff; Marco Calafiore; Lee-Way Jin
Does microglial dysfunction play a role in autism and Rett syndrome?
Neuron glia biology 2011;7(1):85-97.
2010: Heike Wulff
Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers: WO2010066840.
Expert opinion on therapeutic patents 2010;20(12):1759-65.
2010: Pavel I Zimin; Bojan Garic; Silke B Bodendiek; Cédrick Mahieux; Heike Wulff; Boris S Zhorov
Potassium channel block by a tripartite complex of two cationophilic ligands and a potassium ion.
Molecular pharmacology 2010;78(4):588-99.
2010: Heike Wulff; Neil A Castle
Therapeutic potential of KCa3.1 blockers: recent advances and promising trends.
Expert review of clinical pharmacology 2010;3(3):385-96.
2010: Abeer M Al-Ghananeem; Maggie Abbassi; Srishti Shrestha; Girija Raman; Heike Wulff; Lara Pereira; Aftab A Ansari
Formulation-based approach to support early drug discovery and development efforts: a case study with enteric microencapsulation dosage form development for a triarylmethane derivative TRAM-34; a novel potential immunosuppressant.
Drug development and industrial pharmacy 2010;36(5):563-9.
2010: Ralf Köhler; Brajesh P Kaistha; Heike Wulff
Vascular KCa-channels as therapeutic targets in hypertension and restenosis disease.
Expert opinion on therapeutic targets 2010;14(2):143-55.
2010: Lie Di; Shekhar Srivastava; Olga Zhdanova; Yi Ding; Zhai Li; Heike Wulff; Maria Lafaille; Edward Y Skolnik
Inhibition of the K+ channel KCa3.1 ameliorates T cell-mediated colitis.
Proceedings of the National Academy of Sciences of the United States of America 2010;107(4):1541-6.
2010: W Nguyen; B L Howard; D S Neale; Philip E Thompson; P J White; Heike Wulff; David T Manallack
Use of Kv1.3 blockers for inflammatory skin conditions.
Current medicinal chemistry 2010;17(26):2882-96.
2009: Heike Wulff; Neil A Castle; Luis A Pardo
Voltage-gated potassium channels as therapeutic targets.
Nature reviews. Drug discovery 2009;8(12):982-1001.
2009: Shekhar Srivastava; Lie Di; Olga Zhdanova; Zhai Li; Santosha Vardhana; Qi Wan; Ying Yan; Rajat Varma; Jonathan M Backer; Heike Wulff; Michael L Dustin; Edward Y Skolnik
The class II phosphatidylinositol 3 kinase C2beta is required for the activation of the K+ channel KCa3.1 and CD4 T-cells.
Molecular biology of the cell 2009;20(17):3783-91.
2009: Ivica Grgic; Eva Kiss; Brajesh P Kaistha; Christoph Busch; Michael Kloss; Julia Sautter; Anja Müller; Anuradha Kaistha; Claudia Schmidt; Girija Raman; Heike Wulff; Frank Strutz; Hermann-Josef Gröne; Ralf Köhler; Joachim Hoyer
Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(34):14518-23.
2009: Peter Bradding; Heike Wulff
The K+ channels K(Ca)3.1 and K(v)1.3 as novel targets for asthma therapy.
British journal of pharmacology 2009;157(8):1330-9.
2009: Ivica Grgic; Heike Wulff; I Eichler; C Flothmann; Ralf Köhler; Joachim Hoyer
Blockade of T-lymphocyte KCa3.1 and Kv1.3 channels as novel immunosuppression strategy to prevent kidney allograft rejection.
Transplantation proceedings 2009;41(6):2601-6.
2009: Sebastian Brähler; Anuradha Kaistha; Volker J Schmidt; Stephanie E Wölfle; Christoph Busch; Brajesh P Kaistha; Michael Kacik; Anna-Lena Hasenau; Ivica Grgic; Han Si; Chris T Bond; John P Adelman; Heike Wulff; Cor de Wit; Joachim Hoyer; Ralf Köhler
Genetic deficit of SK3 and IK1 channels disrupts the endothelium-derived hyperpolarizing factor vasodilator pathway and causes hypertension.
Circulation 2009;119(17):2323-32.
2009: Silke B Bodendiek; Cédrick Mahieux; Wolfram Hänsel; Heike Wulff
4-Phenoxybutoxy-substituted heterocycles--a structure-activity relationship study of blockers of the lymphocyte potassium channel Kv1.3.
European journal of medicinal chemistry 2009;44(5):1838-52.
2009: Ananthakrishnan Sankaranarayanan; Girija Raman; Christoph Busch; Tim Schultz; Pavel I Zimin; Joachim Hoyer; Ralf Köhler; Heike Wulff
Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure.
Molecular pharmacology 2009;75(2):281-95.
2008: Shekhar Srivastava; Olga Zhdanova; Lie Di; Zhai Li; Mamdouh Albaqumi; Heike Wulff; Edward Y Skolnik
Protein histidine phosphatase 1 negatively regulates CD4 T cells by inhibiting the K+ channel KCa3.1.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(38):14442-6.
2008: Kazuyoshi Toyama; Heike Wulff; K George Chandy; Philippe Azam; Girija Raman; Takashi Saito; Yoshimasa Fujiwara; David L Mattson; Satarupa Das; James E Melvin; Phillip F Pratt; Ossama A Hatoum; David D Gutterman; David R Harder; Hiroto Miura
The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans.
The Journal of clinical investigation 2008;118(9):3025-37.
2008: Mamdouh Albaqumi; Shekhar Srivastava; Zhai Li; Olga Zhdnova; Heike Wulff; Omar Itani; Darren P Wallace; Edward Y Skolnik
KCa3.1 potassium channels are critical for cAMP-dependent chloride secretion and cyst growth in autosomal-dominant polycystic kidney disease.
Kidney international 2008;74(6):740-9.
2008: Heike Wulff
New light on the "old" chloride channel blocker DIDS.
ACS chemical biology 2008;3(7):399-401.
2008: Darla L Tharp; Brian R Wamhoff; Heike Wulff; G Raman; A Cheong; Douglas K Bowles
Local delivery of the KCa3.1 blocker, TRAM-34, prevents acute angioplasty-induced coronary smooth muscle phenotypic modulation and limits stenosis.
Arteriosclerosis, thrombosis, and vascular biology 2008;28(6):1084-9.
2008: Heike Wulff; Boris S Zhorov
K+ channel modulators for the treatment of neurological disorders and autoimmune diseases.
Chemical reviews 2008;108(5):1744-73.
2007: Lara E Pereira; Francios VILLINGER; Heike Wulff; Ananthakrishnan Sankaranarayanan; G Raman; Aftab A Ansari
Pharmacokinetics, toxicity, and functional studies of the selective Kv1.3 channel blocker 5-(4-phenoxybutoxy)psoralen in rhesus macaques.
Experimental biology and medicine (Maywood, N.J.) 2007;232(10):1338-54.
2007: Heike Wulff; Michael Pennington
Targeting effector memory T-cells with Kv1.3 blockers.
Current opinion in drug discovery & development 2007;10(4):438-45.
2007: Philippe Azam; Ananthakrishnan Sankaranarayanan; Daniel Homerick; Stephen M Griffey; Heike Wulff
Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis.
The Journal of investigative dermatology 2007;127(6):1419-29.
2007: Yuki Moritoki; Zhe-Xiong Lian; Heike Wulff; Guo-Xiang Yang; Ya-Hui Chuang; Ruth Y Lan; Yoshiyuki Ueno; Aftab A Ansari; Ross Coppel; Ian R Mackay; M Eric Gershwin
AMA production in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers.
Hepatology (Baltimore, Md.) 2007;45(2):314-22.
2007: Heike Wulff; Aaron Kolski-Andreaco; Ananthakrishnan Sankaranarayanan; Jean-Marc Sabatier; Vikram Shakkottai
Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications.
Current medicinal chemistry 2007;14(13):1437-57.
2006: Christine Beeton; Heike Wulff; Nathan E Standifer; Philippe Azam; Katherine M Mullen; Michael Pennington; Aaron Kolski-Andreaco; Eric Wei; Alexandra Grino; Debra R Counts; Ping H Wang; Christine J LeeHealey; Brian S Andrews; Ananthakrishnan Sankaranarayanan; Daniel Homerick; Werner W Roeck; Jamshid Tehranzadeh; Kimber L Stanhope; Pavel Zimin; Peter J Havel; Stephen M Griffey; Hans-Günther Knaus; Gerald Nepom; George A Gutman; Peter A Calabresi; K George Chandy
Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(46):17414-9.
2006: Andrew J Harvey; Jonathan B Baell; Nathan Toovey; Daniel Homerick; Heike Wulff
A new class of blockers of the voltage-gated potassium channel Kv1.3 via modification of the 4- or 7-position of khellinone.
Journal of medicinal chemistry 2006;49(4):1433-41.
2006: Stéphanie Mouhat; Georgeta Teodorescu; Daniel Homerick; Violeta Visan; Heike Wulff; Yingliang Wu; Stephan Grissmer; Hervé Darbon; Michel De Waard; Jean-Marc Sabatier
Pharmacological profiling of Orthochirus scrobiculosus toxin 1 analogs with a trimmed N-terminal domain.
Molecular pharmacology 2006;69(1):354-62.
2005: Aguan D Wei; George A Gutman; Richard Aldrich; K George Chandy; Stephan Grissmer; Heike Wulff
International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium channels.
Pharmacological reviews 2005;57(4):463-72.
2005: Alexander Schmitz; Ananthakrishnan Sankaranarayanan; Philippe Azam; Kristina Schmidt-Lassen; Daniel Homerick; Wolfram Hänsel; Heike Wulff
Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases.
Molecular pharmacology 2005;68(5):1254-70.
2005: Horea Rus; CARLOS PARDO-VILLAMIZAR; Lina Hu; Erika Darrah; Cornelia Cudrici; Teodora Niculescu; Florin Niculescu; Katherine M Mullen; Rameeza Allie; Liping Guo; Heike Wulff; Christine Beeton; Susan I V Judge; Douglas A Kerr; Hans-Günther Knaus; K George Chandy; Peter A Calabresi
The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(31):11094-9.
2005: Christine Beeton; Michael Pennington; Heike Wulff; Satendra Singh; Daniel Nugent; George Crossley; Ilya Khaytin; Peter A Calabresi; Chao Chen; George A Gutman; K George Chandy
Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.
Molecular pharmacology 2005;67(4):1369-81.
2005: Stéphanie Mouhat; Violeta Visan; S Ananthakrishnan; Heike Wulff; nicolas andreotti; Stephan Grissmer; Hervé Darbon; Michel De Waard; Jean-Marc Sabatier
K+ channel types targeted by synthetic OSK1, a toxin from Orthochirus scrobiculosus scorpion venom.
The Biochemical journal 2005;385(Pt 1):95-104.
2004: Raymond S Norton; Michael Pennington; Heike Wulff
Potassium channel blockade by the sea anemone toxin ShK for the treatment of multiple sclerosis and other autoimmune diseases.
Current medicinal chemistry 2004;11(23):3041-52.
2004: Heike Wulff; Hans-Günther Knaus; Michael Pennington; K George Chandy
K+ channel expression during B cell differentiation: implications for immunomodulation and autoimmunity.
Journal of immunology (Baltimore, Md. : 1950) 2004;173(2):776-86.
2004: Julia Vennekamp; Heike Wulff; Christine Beeton; Peter A Calabresi; Stephan Grissmer; Wolfram Hänsel; K George Chandy
Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators.
Molecular pharmacology 2004;65(6):1364-74.
2004: K George Chandy; Heike Wulff; Christine Beeton; Michael Pennington; George A Gutman; Michael D Cahalan
K+ channels as targets for specific immunomodulation.
Trends in pharmacological sciences 2004;25(5):280-9.
2004: Jonathan B Baell; Robert W Gable; Andrew J Harvey; Nathan Toovey; Tanja Herzog; Wolfram Hänsel; Heike Wulff
Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3: synthesis and immunosuppressive activity.
Journal of medicinal chemistry 2004;47(9):2326-36.
2004: Stéphanie Mouhat; Amor Mosbah; Violeta Visan; Heike Wulff; Muriel DELEPIERRE; Hervé Darbon; Stephan Grissmer; Michel De Waard; Jean-Marc Sabatier
The 'functional' dyad of scorpion toxin Pi1 is not itself a prerequisite for toxin binding to the voltage-gated Kv1.2 potassium channels.
The Biochemical journal 2004;377(Pt 1):25-36.
2003: George A Gutman; K George Chandy; John P Adelman; Jayashree Aiyar; Douglas A Bayliss; David E Clapham; Manuel Covarriubias; Gary V Desir; Kiyoshi Furuichi; Barry Ganetzky; Maria L Garcia; Stephan Grissmer; Lily Yeh Jan; Andreas Karschin; Donghee Kim; Sabina Kuperschmidt; Yoshihisa Kurachi; Michel Lazdunski; Florian Lesage; Henry A Lester; David McKinnon; Colin G Nichols; Ita O'Kelly; Jonathan Robbins; Gail A Robertson; Bernardo Rudy; Michael Sanguinetti; Susumu Seino; Walter Stuehmer; Michael M Tamkun; Carol A Vandenberg; Aguan Wei; Heike Wulff; Randy S Wymore
International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels.
Pharmacological reviews 2003;55(4):583-6.
2003: Ralf Köhler; Heike Wulff; Ines Eichler; Marlene Kneifel; Daniel Neumann; Andreas Knorr; Ivica Grgic; Doris Kämpfe; Han Si; Judith Wibawa; Robert Real; Klaus Borner; Susanne Brakemeier; Hans-Dieter Orzechowski; Hans-Peter Reusch; Martin Paul; K George Chandy; Joachim Hoyer
Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis.
Circulation 2003;108(9):1119-25.
2003: Heike Wulff; Christine Beeton; K George Chandy
Potassium channels as therapeutic targets for autoimmune disorders.
Current opinion in drug discovery & development 2003;6(5):640-7.
2003: Heike Wulff; Peter A Calabresi; Rameeza Allie; Sung Yun; Michael Pennington; Christine Beeton; K George Chandy
The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS.
The Journal of clinical investigation 2003;111(11):1703-13.
2003: Christine Beeton; Heike Wulff; Satendra Singh; Steve Botsko; George Crossley; George A Gutman; Michael D Cahalan; Michael Pennington; K George Chandy
A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes.
The Journal of biological chemistry 2003;278(11):9928-37.
2002: Tokiyoshi Ayabe; Heike Wulff; Dalila Darmoul; Michael D Cahalan; K George Chandy; Andre J Ouellette
Modulation of mouse Paneth cell alpha-defensin secretion by mIKCa1, a Ca2+-activated, intermediate conductance potassium channel.
The Journal of biological chemistry 2002;277(5):3793-800.
2002: Soraya Bardien-Kruger; Heike Wulff; Zainu Arieff; Paul Brink; K George Chandy; Valerie A Corfield
Characterisation of the human voltage-gated potassium channel gene, KCNA7, a candidate gene for inherited cardiac disorders, and its exclusion as cause of progressive familial heart block I (PFHBI).
European journal of human genetics : EJHG 2002;10(1):36-43.
2001: Christine Beeton; Heike Wulff; Jocelyne Barbaria; O Clot-Faybesse; Michael Pennington; Dominique Bernard; Michael D Cahalan; K George Chandy; Evelyne Béraud
Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(24):13942-7.
2001: Vikram Shakkottai; Imed Regaya; Heike Wulff; Ziad Fajloun; Hiroaki Tomita; Mohamed Fathallah; Michael D Cahalan; J Jay Gargus; Jean-Marc Sabatier; K George Chandy
Design and characterization of a highly selective peptide inhibitor of the small conductance calcium-activated K+ channel, SkCa2.
The Journal of biological chemistry 2001;276(46):43145-51.
2001: K G Chandy; Michael D Cahalan; Michael Pennington; Raymond S Norton; Heike Wulff; George A Gutman
Potassium channels in T lymphocytes: toxins to therapeutic immunosuppressants.
Toxicon : official journal of the International Society on Toxinology 2001;39(9):1269-76.
2001: Heike Wulff; George A Gutman; Michael D Cahalan; K George Chandy
Delineation of the clotrimazole/TRAM-34 binding site on the intermediate conductance calcium-activated potassium channel, IKCa1.
The Journal of biological chemistry 2001;276(34):32040-5.
2001: M D Cahalan; Heike Wulff; K George Chandy
Molecular properties and physiological roles of ion channels in the immune system.
Journal of clinical immunology 2001;21(4):235-52.
2001: CM Fanger; H Rauer; AL Neben; Mark J Miller; H Rauer; Heike Wulff; J C Rosa; C R Ganellin; K George Chandy; Michael D Cahalan
Calcium-activated potassium channels sustain calcium signaling in T lymphocytes. Selective blockers and manipulated channel expression levels.
The Journal of biological chemistry 2001;276(15):12249-56.
2001: D Hinck; Heike Wulff; E Koppenhöfer
Gallamine triethiodide selectively blocks voltage-gated potassium channels in Ranvier nodes.
General physiology and biophysics 2001;20(1):83-95.
2000: T Düring; F Gerst; Wolfram Hänsel; Heike Wulff; E Koppenhöfer
Effects of three alkoxypsoralens on voltage gated ion channels in Ranvier nodes.
General physiology and biophysics 2000;19(4):345-64.
2000: S Ghanshani; Heike Wulff; Mark J Miller; H Rohm; AL Neben; George A Gutman; Michael D Cahalan; K George Chandy
Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences.
The Journal of biological chemistry 2000;275(47):37137-49.
2000: Heike Wulff; Mark J Miller; W Hansel; Stephan Grissmer; Michael D Cahalan; K George Chandy
Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(14):8151-6.
2000: Ulf Strauss; K Wissel; Stefan Jung; Heike Wulff; Wolfram Hänsel; J Zhu; Arndt Rolfs; Eilhard Mix
K(+) channel-blocking alkoxypsoralens inhibit the immune response of encephalitogenic T line cells and lymphocytes from Lewis rats challenged for experimental autoimmune encephalomyelitis.
Immunopharmacology 2000;48(1):51-63.
1998: Heike Wulff; H Rauer; T Düring; C Hanselmann; K Ruff; Anja Wrisch; Stephan Grissmer; Wolfram Hänsel
Alkoxypsoralens, novel nonpeptide blockers of Shaker-type K+ channels: synthesis and photoreactivity.
Journal of medicinal chemistry 1998;41(23):4542-9.